Semaglutide for Weight Loss: Hospital Availability in India
Semaglutide's regulatory status, pricing shifts and supply reality in India, and what reliable hospital pharmacy stocking of GLP-1 therapy actually requires.
This covers what CDSCO has actually approved, why pricing moved so sharply, what WHO's own guidance says about long-term use and supply, and what that means for keeping semaglutide reliably in stock inside a hospital.
What has CDSCO actually approved semaglutide for?
CDSCO's Subject Expert Committee on Endocrinology and Metabolism recommended approval of semaglutide solution for chronic weight management in adults with an initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbid condition, conditional on the manufacturer running a post-marketing surveillance study. Semaglutide injection and tablet formulations for type 2 diabetes had earlier approvals dating to 2020 and 2022.
Novo Nordisk's post-marketing study protocol for Wegovy in India, titled STEP REAL INDIA, was presented to evaluate real-world safety and effectiveness in adults with overweight or obesity in routine Indian clinical practice. That surveillance requirement means the obesity indication in India still carries an active data-collection obligation, not a closed approval file.
Why did semaglutide pricing change so sharply in 2026?
Novo Nordisk cut Ozempic and Wegovy prices by up to 48% in April 2026, bringing the 0.25 mg starter pen down to roughly ₹5,660 a month with the 0.5 mg dose running ₹7,200–8,800 monthly, well below the ₹8,800–16,400 range the products carried through 2025. The cut followed the same pattern seen in other markets once patent-expiry generic competition became imminent.
Generic semaglutide from domestic manufacturers, including several major Indian pharmaceutical companies that received CDSCO clearance after the March 2026 patent expiry, now starts from around ₹325 per weekly vial-format injection for the 0.25 mg starting dose. That is a fraction of even the discounted branded price, and it is the single biggest driver of how fast semaglutide access has widened in India this year.
What does WHO's guidance say about supply and long-term use?
WHO added GLP-1 medicines, including semaglutide, to its Model List of Essential Medicines for type 2 diabetes and obesity-related indications, while explicitly flagging affordability and supply as the constraints standing between the guidance and real-world access. WHO's own statement on the listing named high prices as the primary barrier and pointed to generic entry as the mechanism expected to close that gap.
WHO's GLP-1 guideline further recommends long-term, continuous use where clinically appropriate rather than a short defined course, which has direct supply implications: a therapy meant to be taken for months or years needs a hospital pharmacy that can guarantee continuity, not just an initial fill. A patient who starts and then can't reliably continue loses the metabolic benefit the therapy was meant to deliver.
Why has semaglutide had documented shortages even as demand grew?
Rising off-label and cosmetic-weight-loss demand for semaglutide has repeatedly strained supply meant for patients with type 2 diabetes, a pattern documented internationally as the drug's popularity outpaced manufacturing capacity. India's market saw a version of the same dynamic through 2025, before generic entry in 2026 substantially eased it.
A hospital pharmacy stocking semaglutide for genuine endocrinology or bariatric-medicine patients competes for the same limited early supply as a much larger pool of self-referred or aesthetic-clinic demand, which is precisely why supply reliability, not price alone, has been the harder problem to solve until generic volume caught up.
What should a hospital pharmacy consider when stocking semaglutide?
A hospital pharmacy stocking semaglutide needs a formulary decision between the branded product (with its post-marketing surveillance data trail and manufacturer supply chain) and the newer CDSCO-approved generics, weighed against patient continuity needs and ward-level demand. Because WHO's own guidance treats this as a long-term therapy, a pharmacy that stocks inconsistently effectively breaks the treatment course every time a patient can't get a refill on schedule.
This is where reliable in-house stocking becomes a genuine continuity-of-care issue rather than just a commercial one. When a hospital's own pharmacy can't consistently supply the specific semaglutide product a patient has been titrated onto, that patient either goes without a dose, switches products mid-course in a way their endocrinologist did not plan, or takes the prescription to an outside chemist and may not come back for follow-up care at all. A managed or in-house hospital pharmacy that tracks genuine GLP-1 demand and stocks against it protects both the patient's continuity and the prescription's place inside the hospital rather than losing it to leakage. Medyzen's guides on managed hospital pharmacy services, prescription leakage and hospital revenue loss, and pharmacy inventory management for expiry and dead stock cover this operational gap in more depth, including how a fast-moving, high-value cold-chain product like semaglutide should be reordered without tying up capital in dead stock.
Does India have price controls on semaglutide?
Semaglutide is not currently listed as a scheduled formulation under the Drug Price Control Order administered by the National Pharmaceutical Pricing Authority, which is why its branded price moved on manufacturer decision rather than a government-set ceiling. The 2026 price cut was a commercial response to imminent generic competition, not a regulatory mandate.
That leaves hospital procurement teams comparing branded and generic pricing directly, product by product, the same way they would for any non-scheduled drug, rather than relying on an NPPA ceiling price as a reference point.
Sources
- 1SEC (Endocrinology & Metabolism) meeting recommendations, 09.12.2025 — Central Drugs Standard Control Organisation
- 2SEC (Endocrinology & Metabolism) meeting recommendations, 16.10.2025 — Central Drugs Standard Control Organisation
- 3WHO adds new medicines for weight management and diabetes to Essential Medicines Lists — World Health Organization
- 4WHO guideline on the use of GLP-1 receptor agonists for adults living with obesity — World Health Organization
- 5National Pharmaceutical Pricing Authority — Drug Price Control Order scheduled formulations list
This article is for informational purposes and is not a substitute for professional medical advice. Semaglutide requires individualised clinical assessment and prescription; consult a qualified physician before starting or continuing any GLP-1 therapy.
FAQ
Frequently asked questions
Yes. CDSCO's Subject Expert Committee recommended approval of semaglutide solution for chronic weight management in adults with obesity (BMI ≥30) or overweight with a comorbidity (BMI ≥27), conditional on the manufacturer running a post-marketing surveillance study in India.
Branded Wegovy and Ozempic run roughly ₹5,660–8,800 a month after Novo Nordisk's April 2026 price cut, while CDSCO-approved generic semaglutide starts from around ₹325 per weekly injection at the 0.25 mg starting dose, following patent expiry in March 2026.
Demand for semaglutide, including substantial off-label and cosmetic-weight-loss use, outpaced manufacturing supply meant for diabetes and clinically indicated obesity treatment, a pattern documented internationally through 2025 before Indian generic manufacturers received CDSCO approval in 2026.
WHO's GLP-1 guideline recommends long-term, continuous use where clinically appropriate, rather than a defined short course, which is why consistent hospital pharmacy stocking matters as much as the initial prescription for patients on this therapy.
No. Semaglutide is not currently listed as a scheduled formulation under the Drug Price Control Order, so its price is set by manufacturers rather than an NPPA ceiling, which is why the 2026 price cuts were a commercial decision tied to generic competition.
Dr. Ananya DeshpandeMBBS, DM (Endocrinology)
Consultant Endocrinologist
Dr. Ananya Deshpande is a consultant endocrinologist writing on diabetes and insulin therapy, thyroid disorders, GLP-1 agonists, and metabolic conditions.